TransMedics Reports First Quarter 2026 Financial Results
TransMedics reported Q1 2026 revenue of $173.9 million, up 21% year-over-year, driven by increased utilization of its Organ Care System and growth in logistics services. Despite the revenue growth, operating margins contracted to 7.6% from 19.1% in the prior year due to higher investments in R&D and expansion costs, resulting in GAAP EPS of $0.20 compared to $0.70 last year.
Key figures
- Eps
- 0.2
- Revenue
- 173900000
- Guidance
- FY2026 revenue $727 million to $757 million
- Revenue Yoy
- 21%
- Net income
- 7300000
- Adjusted eps
- 0.3
- Gross margin
- 58%
- Aircraft owned
- 22
- Operating income
- 13297000
- Adjusted net income
- 10900000
- Adjusted operating income
- 18109000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.